tbuckley/cabot-search huggingface dataset:
Defining circadian disruption in neurodegenerative disorders
Authors: Christopher S. Colwell
Journal: Journal of Clinical Investigation (2021)

Neurodegenerative diseases encompass a large group of conditions that are clinically and pathologically diverse yet are linked by a shared pathology of misfolded proteins. The accumulation of insoluble aggregates is accompanied by a progressive loss of vulnerable neurons. For some patients, the symptoms are motor focused (ataxias), while others experience cognitive and psychiatric symptoms (dementias). Among the shared symptoms of neurodegenerative diseases is a disruption of the sleep/wake cycle that occurs early in the trajectory of the disease and may be a risk factor for disease development. In many cases, the disruption in the timing of sleep and other rhythmic physiological markers immediately raises the possibility of neurodegeneration-driven disruption of the circadian timing system. The aim of this Review is to summarize the evidence supporting the hypothesis that circadian disruption is a core symptom within neurodegenerative diseases, including Alzheimer's disease, Huntington's disease, and Parkinson's disease, and to discuss the latest progress in this field. The Review discusses evidence that neurodegenerative processes may disrupt the structure and function of the circadian system and describes circadian-based interventions as well as timed drug treatments that may improve a wide range of symptoms associated with neurodegenerative disorders. It also identifies key gaps in our knowledge.
707P Treatment pattern and overall survival among patients with locally advanced or metastatic urothelial carcinoma: Results from a complete nationwide unselected real-world registry study in Denmark from 2010 to 2017
Authors: J.B. Jensen, D.S. Hauberg, M. Duus Hjortsoe, M.E. Madsen, J. Olsen, M. Agerbæk
Journal: Annals of Oncology (2021)
1108P Folfirinox in the treatment of advanced gastroenteropancreatic neuroendocrine carsinomas
Authors: B.P. Butt, H.L. Stokmo, M. Ladekarl, E. Mitkina Tabaksblat, H. Sorbye, M.E. Revheim, G.O. Hjortland
Journal: Annals of Oncology (2021)
1294P 18F-FDG PET-TC derived parameters as a tool to select pembrolizumab single agent or in combination with chemotherapy in first-line NSCLC
Authors: F.G. Dall'Olio, None C. Garcia, A. Bettaieb, M. Naigeon, F. Facchinetti, F-X. Danlos, C. Caramella, J.C. Benitez, M. Aldea, F. Blanc-Durand, C. Naltet, P. Abdayem, P. Lavaud, M.R. Ghigna, N. Chaput, A. Marabelle, D. Planchard, F. Barlesi, J-C. Soria, B. Besse
Journal: Annals of Oncology (2021)
1783P Multi-parametric T cells profiling in broncho-alveolar lavage fluid (BAL) and blood from advanced lung cancer patients
Authors: A. Mariniello, F. Tabbò, D. Indellicati, M. Geuna, M. Tesauro, N.A. Rezmives, M. Di Maio, P. Bironzo, M.L. Reale, F. Passiglia, A. Listi, E. Capelletto, S. Carnio, V. Bertaglia, C. Mecca, L.T. Consito, M. De Filippis, M. Bungaro, C. Paratore, S. Novello
Journal: Annals of Oncology (2021)
Accuracy of the Patient Health Questionnaire-9 for screening to detect major depression: updated systematic review and individual participant data meta-analysis
Authors: Zelalem F Negeri, Brooke Levis, Ying Sun, Chen He, Ankur Krishnan, Yin Wu, Parash Mani Bhandari, Dipika Neupane, Eliana Brehaut, Andrea Benedetti, Brett D Thombs
Journal: BMJ (2021)

Abstract Objective To update a previous individual participant data meta-analysis and determine the accuracy of the Patient Health Questionnaire-9 (PHQ-9), the most commonly used depression screening tool in general practice, for detecting major depression overall and by study or participant subgroups. Design Systematic review and individual participant data meta-analysis. Data sources Medline, Medline In-Process, and Other Non-Indexed Citations via Ovid, PsycINFO, Web of Science searched through 9 May 2018. Review methods Eligible studies administered the PHQ-9 and classified current major depression status using a validated semistructured diagnostic interview (designed for clinician administration), fully structured interview (designed for lay administration), or the Mini International Neuropsychiatric Interview (MINI; a brief interview designed for lay administration). A bivariate random effects meta-analytic model was used to obtain point and interval estimates of pooled PHQ-9 sensitivity and specificity at cut-off values 5-15, separately, among studies that used semistructured diagnostic interviews (eg, Structured Clinical Interview for Diagnostic and Statistical Manual), fully structured interviews (eg, Composite International Diagnostic Interview), and the MINI. Meta-regression was used to investigate whether PHQ-9 accuracy correlated with reference standard categories and participant characteristics. Results Data from 44 503 total participants (27 146 additional from the update) were obtained from 100 of 127 eligible studies (42 additional studies; 79% eligible studies; 86% eligible participants). Among studies with a semistructured interview reference standard, pooled PHQ-9 sensitivity and specificity (95% confidence interval) at the standard cut-off value of ≥10, which maximised combined sensitivity and specificity, were 0.85 (0.79 to 0.89) and 0.85 (0.82 to 0.87), respectively. Specificity was similar across reference standards, but sensitivity in studies with semistructured interviews was 7-24% (median 21%) higher than with fully structured reference standards and 2-14% (median 11%) higher than with the MINI across cut-off values. Across reference standards and cut-off values, specificity was 0-10% (median 3%) higher for men and 0-12 (median 5%) higher for people aged 60 or older. Conclusions Researchers and clinicians could use results to determine outcomes, such as total number of positive screens and false positive screens, at different PHQ-9 cut-off values for different clinical settings using the knowledge translation tool at www.depressionscreening100.com/phq . Study registration PROSPERO CRD42014010673.
What's not music, but feels like music to you?
Authors: Vijay Iyer
Journal: Behavioral and Brain Sciences (2021)

Abstract The category “music” as used in this area of science is inconsistent and unstable, and its logical relationship to the word “musicality” – used by scientists to denote the human capacity for music – is circular. Therefore, rather than pursue the question, “Why did music(ality) evolve?” let us ask more inclusively, “What experiences in humankind's deep past might have felt like music ?”
1675P Potential effect of adipose tissue distribution on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients (pts) receiving first-line pembrolizumab (PEMBRO)
Authors: I. Trestini, M. Cintoni, M. Sposito, D. Kadrija, A. Dodi, A. Caldart, L. Belluomini, J. Menis, E. Vita, I. Sperduti, A. Drudi, G. Aluffi, D. Tregnago, A. Avancini, M. D'Onofrio, M.C. Mele, G. Tortora, M. Milella, E. Bria, S. Pilotto
Journal: Annals of Oncology (2021)
880P Systematic literature review (SLR) of randomized controlled trials in patients (pts) with newly diagnosed locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) ineligible for surgery
Authors: K. Ramakrishnan, P. Wu, C.M. Black, S. Keeping, N. Upadhyay, A. Mojebi
Journal: Annals of Oncology (2021)
1083P A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint inhibitor refractory advanced or unresectable melanoma
Authors: A.N. Shoushtari, A.J. Olszanski, M. Nyakas, T.J. Hornyak, J.D. Wolchok, V. Levitsky, A-S. Møller, L. Kuryk, K. Risberg Handeland, M. Jäderberg
Journal: Annals of Oncology (2021)
559TiP A phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN inactivating mutations
Authors: J. Rodon, P. Funchain, T.W. Laetsch, C.F. Singer, H-T. Arkenau, S.P. Chawla, A. Hervieu, I. Yamamiya, M. Liu, K.A. Benhadji, O. Takahashi, S. Delaloge
Journal: Annals of Oncology (2021)
LBA11 Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer
Authors: H.M. Earl, L. Hiller, J.A. Dunn, P.F. Conte, R. D'Amico, V. Guarneri, H. Joensuu, T. Huttunen, V. Georgoulias, J. Abraham, D. Cameron, D.W. Miles, A.M. Wardley, G. Romieu, M. Debled, C. Faure-Mercier, H. Lindman, J. Fraser, D. Cox, X. Pivot
Journal: Annals of Oncology (2021)
1724P Prognostic parameters at admission as predictors of hospital length of stay (HLOS) and overall survival (OS) in hospitalized oncologic patients (pts) of a tertiary hospital
Authors: O. Mirallas, D. López-Valbuena, G. Villacampa Javierre, K.S. Vega, D. Gómez-Puerto, C. Salva-Torres, A. Rezqallah, G. Molina, J. Aguilar-Company, M. Roca, L. Andurell, F. Palmas, M.E. Elez Fernandez, A. Alonso, P. Gomez-Pardo, S. Serradell, J. Tabernero, E. Felip, A. Peñuelas, J. Carles
Journal: Annals of Oncology (2021)
1482P Landscape of germline pathogenic variants beyond BRCA in pancreatic cancer patients
Authors: R. Borea, A. Puccini, V. Andreotti, L. Pastorino, I. Vanni, F. Catalano, S. Puglisi, W. Bruno, B. Dalmasso, A. Signori, G. Fornarini, P. Ghiorzo, S. Sciallero
Journal: Annals of Oncology (2021)
445P Tumor load surrogates as major prognostic factors in BRAF-V600E mutated (mt) colorectal (CRC) patients treated with BRAF inhibitor+antiEGFR +/- MEK inhibitor
Authors: F.J. Ros Montana, G. Martini, G. Villacampa Javierre, I. Baraibar, R. Comas, A. Garcia, F. Salva, N. Saoudi Gonzalez, D. Ciardiello, R.D.A. Toledo, E. Martinelli, F. Ciardiello, A. Vivancos, H.G. Palmer, R. Dienstmann, J. Tabernero, M.E. Elez Fernandez
Journal: Annals of Oncology (2021)
Comparison of 2 Midline Catheter Devices With Differing Antithrombogenic Mechanisms for Catheter-Related Thrombosis
Authors: Amit Bahl, Emily Diloreto, David Jankowski, Mahmoud Hijazi, Nai-Wei Chen
Journal: JAMA Network Open (2021)

<h3>Importance</h3> Data regarding upper extremity midline catheter (MC)–related thrombosis (CRT) are sparse, with some evidence indicating that MCs have a high rate of CRT. <h3>Objective</h3> To compare 2 MCs with differing antithrombogenic mechanisms for this outcome. <h3>Design, Setting, and Participants</h3> In this parallel, 2-arm randomized clinical trial, 496 adult patients hospitalized at a tertiary care suburban academic medical center who received an MC were assessed for eligibility between January 1, 2019, and October 31, 2020, and 212 were randomized. <h3>Interventions</h3> Inpatients were randomized to receive a 4F antithrombotic MC (MC-AT) or a 4.5F antithrombotic and antimicrobial MC (MC-AT-AM). <h3>Main Outcomes and Measures</h3> The primary outcome was symptomatic midline CRT inclusive of deep vein thrombosis or superficial venous thrombophlebitis within 30 days after insertion. Secondary outcomes included catheter-associated bloodstream infection and catheter failure. <h3>Results</h3> A total of 191 patients (mean [SD] age, 60.2 [16.7] years; 114 [59.7%] female) were included in the final analysis: 94 patients in the MC-AT group and 97 in the MC-AT-AM group. Symptomatic midline CRT occurred in 7 patients (7.5%) in the MC-AT group and 11 (11.3%) in the MC-AT-AM group (<i>P</i> = .46). Deep vein thrombosis occurred in 5 patients (5.3%) in the MC-AT group and 5 patients (5.2%) in the MC-AT-AM group (<i>P</i> &gt; .99). Pulmonary embolism occurred in 1 patient in the MC-AT group. No catheter-associated bloodstream infection occurred in either group. Premature catheter failure occurred in 22 patients (23.4%) in the MC-AT group and 20 (20.6%) in the MC-AT-AM group (<i>P</i> = .64). In Cox proportional hazards regression analysis, no statistically significant difference was found between groups for the risk of catheter failure (hazard ratio, 1.27; 95% CI, 0.67-2.43;<i>P</i> = .46). <h3>Conclusions and Relevance</h3> No difference was found in thrombosis in MCs with 2 distinct antithrombogenic mechanisms; however, the risk of CRT in both groups was high. Practitioners should strongly consider the safety risks associated with MCs when determining the appropriate vascular access device. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT03725293
Surgical excision margins for fibrohistiocytic tumors, including atypical fibroxanthoma and undifferentiated pleomorphic sarcoma: A probability model based on a systematic review
Authors: Atieh Jibbe, Brandon Worley, Corinne H. Miller, Murad Alam
Journal: Journal of the American Academy of Dermatology (2021)

Mohs micrographic surgery or wide local excision is the treatment of choice for fibrohistiocytic tumors with metastatic potential, including atypical fibroxanthoma (AFX) and cutaneous undifferentiated pleomorphic sarcoma (cUPS). Since margin clearance is the strongest predictor of clinical recurrence, improved recommendations for appropriate surgical margins help delineate uniform excision margins when intraoperative margin assessment is not available.To determine appropriate surgical wide local excision margins for AFX and cUPS.Literature search (Ovid MEDLINE, Embase, Web of Science, and Cochrane Library from inception to March 2020) to detect case-level data. Estimation of margins required using a mathematical model based on extracted cases without recurrences.Probabilistic modeling based on 100 cases extracted from 37 studies showed peripheral clearance margin (ie, wide local excision margin) calculated to clear 95% of all tumors was 2 cm for AFX and 3 cm for cUPS. AFX tumors 1 cm or less required a margin of 1 cm.Data were extracted from published cases.Atypical fibroxanthoma removed with at least a 2-cm peripheral excision margin is less likely to recur. Smaller tumors 1 cm or less can be treated with a more conservative margin. Margin-control surgical techniques are recommended to ensure complete removal while minimizing surgical morbidity.
1193MO Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2
Authors: C.A. Shu, K. Goto, Y. Ohe, B. Besse, K. Park, Y. Wang, F. Griesinger, J.C-H. Yang, E. Felip, R.E. Sanborn, R. Bernabe Caro, J.M. Bauml, J. Chen, E. Fennema, J. Mahoney, L. Trani, R.E. Knoblauch, M. Thayu, B.C. Cho
Journal: Annals of Oncology (2021)
CN22 Importance of research nursing role determining the germline study in metastatic prostate cancer patients
Authors: P. Peinado Ferreira, C. Llacer Perez, G. Grau, L. Oliva Fernandez, E. Cañada-Higueras, B. Herrera-Imbroda, D. Hernández, M.I. Sáez, R. Villatoro, A. Montesa Pino, F.J. López, M. Márquez, A. Pineda, D. Olmos, E. Castro
Journal: Annals of Oncology (2021)
Methods of Public Health Research — Strengthening Causal Inference from Observational Data
Authors: Miguel A. Hernán
Journal: New England Journal of Medicine (2021)

Interview with Dr. Miguel Hernán on the use of observational data to inform public health and clinical care decisions. (09:24)Download For researchers using observational data, a useful way to answer a causal question is to design the target trial that would answer it and then emulate its protocol. The example of the HIV-treatment-as-prevention strategy illustrates the benefits of this approach.
497P Correction of geriatric status in patients with metastatic colorectal cancer
Authors: Y.V. Alekseeva, T.Y. Semiglazova, S.M. Sharashenidze, E.V. Tkachenko, S.V. Kondratiev, N.A. Brish, L.V. Filatova, G.M. Teletaeva, D.K. Latipova, M.I. Sluzhev, R.V. Donskikh, V.V. Semiglazov, B.S. Kasparov, S.A. Protsenko, A.M. Belyaev
Journal: Annals of Oncology (2021)
A Modified Nucleoside 6-Thio-2′-Deoxyguanosine Exhibits Antitumor Activity in Gliomas
Authors: Shengnan Yu, Shiyou Wei, Milan Savani, Xiang Lin, Kuang Du, Ilgen Mender, Silvia Siteni, Themistoklis Vasilopoulos, Zachary J. Reitman, Yin Ku, Di Wu, Hao Liu, Meng Tian, Yaohui Chen, Marilyne Labrie, Casey M. Charbonneau, Eric Sugarman, Michelle Bowie, Seethalakshmi Hariharan, Matthew Waitkus, Wen Jiang, Roger E. McLendon, Edward Pan, Mustafa Khasraw, Kyle M. Walsh, Yiling Lu, Meenhard Herlyn, Gordon Mills, Utz Herbig, Zhi Wei, Stephen T. Keir, Keith Flaherty, Lunxu Liu, Kongming Wu, Jerry W. Shay, Kalil Abdullah, Gao Zhang, David M. Ashley
Journal: Clinical Cancer Research (2021)

To investigate the therapeutic role of a novel telomere-directed inhibitor, 6-thio-2'-deoxyguanosine (THIO) in gliomas both in vitro and in vivo.A panel of human and mouse glioma cell lines was used to test therapeutic efficacy of THIO using cell viability assays, flow cytometric analyses, and immunofluorescence. Integrated analyses of RNA sequencing and reverse-phase protein array data revealed the potential antitumor mechanisms of THIO. Four patient-derived xenografts (PDX), two patient-derived organoids (PDO), and two xenografts of human glioma cell lines were used to further investigate the therapeutic efficacy of THIO.THIO was effective in the majority of human and mouse glioma cell lines with no obvious toxicity against normal astrocytes. THIO as a monotherapy demonstrated efficacy in three glioma cell lines that had acquired resistance to temozolomide. In addition, THIO showed efficacy in four human glioma cell lines grown as neurospheres by inducing apoptotic cell death. Mechanistically, THIO induced telomeric DNA damage not only in glioma cell lines but also in PDX tumor specimens. Integrated computational analyses of transcriptomic and proteomic data indicated that THIO significantly inhibited cell invasion, stem cell, and proliferation pathways while triggering DNA damage and apoptosis. Importantly, THIO significantly decreased tumor proliferation in two PDO models and reduced the tumor size of a glioblastoma xenograft and a PDX model.The current study established the therapeutic role of THIO in primary and recurrent gliomas and revealed the acute induction of telomeric DNA damage as a primary antitumor mechanism of THIO in gliomas.
805P Clinically actionable alterations in adolescents and young adults (AYA) with gynaecological cancers
Authors: A. Madariaga Urrutia, L. Bonilla, I. King, S. Garg, V. Bowering, N. Dhani, M. Milosevic, K. Han, K. Lajkosz, K. Karakasis, P. Ghiassi, S. Siman, M. Rouzbahman, G. Downs, N. Park, C. Sheen, S. Udagani, T. Stockley, A.M. Oza, S. Lheureux
Journal: Annals of Oncology (2021)
Music as a trait in evolutionary theory: A musicological perspective
Authors: Melanie Wald-Fuhrmann, Lara Pearson, Tina Roeske, Christian Grüny, Rainer Polak
Journal: Behavioral and Brain Sciences (2021)

Abstract Although it can be straightforward to define the features of physical traits, complex cultural categories tend to elude widely accepted definitions that transcend cultural and historical context. Addressing papers by Mehr et al. and Savage et al., which both aim to explain music as an evolved trait, we discuss fundamental problems that arise from their conceptualizations of music.
973P A phase II study of PDR001 among patients with recurrent and/or metastatic esophageal squamous cell carcinoma: An interim analysis of KM-12
Authors: D.K. Lee, S.R. Park, Y.H. Kim, Y-G. Lee, B-C. Ahn, S.M. Lim, H.R. Kim, B.C. Cho, M.H. Hong
Journal: Annals of Oncology (2021)
1123O Evaluation of cell-free DNA approaches for multi-cancer early detection
Authors: M.C. Liu, A. Jamshidi, E.A. Klein, O. Venn, E. Hubbell, J.F. Beausang, N. Zhang, K.N. Kurtzman, C. Hou, D.A. Richards, T.J. Yeatman, A.L. Cohn, D.D. Thiel, M.K. Tummala, K. McIntyre, M.A. Sekeres, A.H. Bryce, M.V. Seiden, C. Swanton
Journal: Annals of Oncology (2021)
Centering Equity in Health Care
Authors: Elaine M. Hernandez
Journal: JAMA Pediatrics (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Making music: Let's not be too quick to abandon the byproduct hypothesis
Authors: Steve Stewart-Williams
Journal: Behavioral and Brain Sciences (2021)

It is premature to conclude that music is an adaptation. Given the danger of overextending the adaptationist mode of explanation, the default position should be the byproduct hypothesis, and it should take very strong evidence to drag us into the adaptationist camp. As yet, the evidence isn't strong enough - and the proposed adaptationist explanations have a number of unresolved difficulties.
Patient Adherence to Lung CT Screening Reporting &amp; Data System–Recommended Screening Intervals in the United States: A Systematic Review and Meta-Analysis
Authors: Yannan Lin, Mingzhou Fu, Ruiwen Ding, Kosuke Inoue, Christie Y. Jeon, William Hsu, Denise R. Aberle, Ashley Elizabeth Prosper
Journal: Journal of Thoracic Oncology (2021)

Lung cancer screening (LCS) is effective in reducing mortality, particularly when patients adhere to follow-up recommendations standardized by the Lung CT Screening Reporting & Data System (Lung-RADS). Nevertheless, patient adherence to recommended intervals varies, potentially diminishing benefit from screening. We conducted a systematic review and meta-analysis of patient adherence to Lung-RADS-recommended screening intervals. We systematically searched MEDLINE, EMBASE, Web of Science, the Cochrane Central Register of Controlled Trials, and major radiology and oncology conference archives between April 28, 2014, and December 17, 2020. Eligible studies mentioned patient adherence to the recommendations of Lung-RADS. The review protocol was registered with PROSPERO (CRD42020189326). We identified 24 eligible studies for qualitative summary, of which 21 were suitable for meta-analysis. The pooled adherence rate was 57% (95% confidence interval: 46%-69%) for defined adherence (e.g., an annual incidence screen was performed within 15 mo) among 6689 patients and 65% (95% confidence interval: 55%-75%) for anytime adherence among 5085 patients. Large heterogeneity in adherence rates between studies was observed (I2 = 99% for defined adherence, I2 = 98% for anytime adherence). Heterogeneous adherence rates were associated with Lung-RADS scores, with significantly higher adherence rates among Lung-RADS 3 to 4 than Lung-RADS 1 to 2 (p < 0.05). Patient adherence to Lung-RADS-recommended screening intervals is suboptimal across clinical LCS programs in the United States, especially among patients with results of Lung-RADS categories 1 to 2. To improve adherence rates, future research may focus on implementing tailored interventions after identifying barriers to LCS. We also propose a minimum standardized set of data elements for future pooled analyses of LCS adherence on the basis of our findings.
P-198 Prevalence of deleterious DPYD variants in patients with gastrointestinal malignancies: Real-world data from a single institution in Italy
Authors: C. Cardone, F. Collina, M. Brogna, R. Casaretti, A. Cassata, A. De Stefano, I. Di Giovanni, A. Nappi, C. Romano, L. Silvestro, G. Viscardi, N. Zanaletti, M. Di Bonito, A. Avallone
Journal: Annals of Oncology (2021)